Assessment of undesirable dose to eye-melanoma patients after proton radiotherapy

Radiotherapy with a proton beam of initial energy 55–80 MeV is presently the clinically recommended therapy for some cases of intraocular melanoma such as large melanomas or tumours adjacent to critical organs. Evaluation and optimization of radiation doses outside the treatment volume may contribute to reducing undesirable side-effects and decreasing the risk of occurrence of secondary cancers, particularly for paediatric patients. In this work the undesired doses to organs were assessed basing on Monte Carlo calculation of secondary radiation transport and on results of measurements of neutron and γ-ray doses at the proton therapy facility of the Institute of Nuclear Physics at Kraków. Dosimetry was performed using a He-3-based FHT 762 neutron monitor (Wendi II), a FH40G proportional counter (for γ-rays), and MTS-7 (LiF:Mg,Ti) thermoluminescence detectors (TLDs). Organ doses were calculated in the ADAM anthropomorphic phantom using the MCNPX Monte Carlo transport code and partly verified, for γ-ray doses, with TLD measurements in the RANDO Anderson anthropomorphic phantom. The effective dose due to undesired radiation, including exposure from scattered radiation during the entire process of proton radiotherapy and patient positioning using X-rays, does not exceed 1 mSv.